Modulation of 11β-Hydroxysteroid Dehydrogenase Expression by Bombesin: A Possible Mechanism for Glucocorticoid Resistance in Androgen Independent Prostate Cancer

Abstract

Treatment with glucocorticoids is one of a limited number of options for androgen independent prostate cancer. Neuroendocrine differentiation has been shown to contribute to androgen-independent prostate cancer progression. To study the potential link between neuroendocrine differentiation and the glucocorticoid action, we investigated the effects of the product of neuroendocrine differentiation – bombesin on glucocorticoid metabolizing enzymes – 11β-hydroxysteroid dehydrogenases in PC-3 cells. Our Western analysis, RT-PCR, and activity assays demonstrate that while 18-hour exposure to bombesin reduces 11β-hydroxy-steroid dehydrogenases-1 profiles (activities 25% less, protein level 29% lower, mRNA levels 45% lower), contrarily it increases 11β-hydroxysteroid dehydrogenases-2 profiles (activities 34%, protein levels 100%, mRNA levels 120%). Blockade bombesin action with bombesin receptor antagonists and the enzyme degrading bombesin prevented these changes, suggesting the observed modulations were bombesin receptor-specific. In addition, bombesin increased the amounts of interleukin-8 and mRNA of vascular endothelial growth factor receptor 2, which were lowered in the presence of cortisol, suggesting that neuropeptide blockade may extend the benefits of glucocorticoids in treating androgen-independent prostate cancer.

glucocorticoid - bombesin - 11β-hydroxysteroid dehydrogenases - neuroendocrine differentiation - prostate cancer

References

• 1 Sadar MD, Hussain M, Bruchovsky N. Prostate cancer: molecular biology of early progression to androgen independence.  Endocrin Relat Cancer. 1999;  6 487-502
• 2 Saika T, Kusaka N, Tsushima T, Yamato T, Ohashi T, Suyama B, Arata R, Nasu Y, Kumon H. Treatment of androgen-independent prostate cancer with dexamethasone: a prospective study in stage D2 patients.  Intl J Urol. 2001;  8 290-294
• 3 Clark AF. Mechanism of action of the angiostatic cortisene anecortave acetate.  Surv Ophthalmol. 2007;  52 ((Suppl)) S26-S34
• 4 Wu WS, Wang FS, Yang KD, Huang C, Kuo Y. Dexamethasone induction of keloid regression through effective suppression of VEGF expres-sion and keloid fibroblast proliferation.  J Invest Dermatol. 2006;  126 1264-1271
• 5 Oliver A, Ciulla TA. Corticosteroids as antiangiogenic agents.  Ophthalmol Clin North Am. 2006;  19 345-351
• 6 Yano A, Fujii Y, Iwai A, Kageyama Y, Kihara K. Glucocorticoids suppress tumor angiogenesis and in vivo growth of prostate cancer cells.  Clin Cancer Res. 2006;  12 3003-3009
• 7 Draper N, Stewart PM. 11β-Hydroxysteroid dehydrogenase and the pre-receptor regulation of corticosteroid hormone action.  J Endo. 2005;  186 251-271
• 8 Ge RS, Dong Q, Niu EM, Sottas CM, Hardy DO, Catterall JF, Latif SA, Morris DJ, Hardy MP. 11β-Hydroxysteroid dehydrogenase 2 in rat leydig cells: its role in blunting glucocorticoid action at physiological levels of substrate.  Endocrinology. 2005;  146 2657-2664
• 9 Kofler R, Schmit S, Kofler A, Ausserlechner MJ. Resistance to glucocorticoid-induced apoptosis in lymphoblastic leukemia.  J Endocrinol. 2003;  178 19-27
• 10 Wu JT, Erickson AJ, Tsao KC, Wu TL, Sun CF. Elevated serum chromogranin A is detectable in patients with carcinomas at advanced disease stages.  Ann Clin Lab Sci. 2000;  30 175-178
• 11 Markwalder R, Reubi JC. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation.  Cancer Res. 1999;  59 1152-1159
• 12 Cornelio DB, Roesler R, Schwartsmann G. Gastrin-releasing peptide receptor as a molecular target in experimental anticancer therapy.  Ann Onc. 2007;  18 1457-1466
• 13 Monder C, Lakshmi V. Corticosteroid 11 beta-dehydrogenase of rat tissues: immunological studies.  Endocrinology. 1990;  126 2435-2443
• 14 Ge RS, Hardy MP. Protein kinase C increases 11beta-hydroxysteroid dehydrogenase oxidation and inhibits reduction in rat Leydig cells.  J Andrology. 2002;  23 135-143
• 15 Gong J, Zhu J, Goodman OB, Pestell RG, Schlegel PN, Nanus DM, Shen R. Activation of p300 histone acetyltransferase activity and acetylation of the androgen receptor by bombesin in prostate cancer cells.  Oncogene. 2006;  23 2011-2021
• 16 Quinkler M, Zehnder D, Lepenies J, Petrelli MD, Moore JS, Hughes SV, Cockwell P, Hewison M, Stewart PM. Expression of renal 11β hydroxysteroid dehydrogenase type 2 is decreased in patients with impaired renal function.  Eur J Endo. 2005;  153 291-299
• 17 Moore JS, Monson JP, Kaltsas G, Putignano P, Wood PJ, Sheppard MC, Besser GM, Taylor NF, Stewart PM. Modulation of 11beta-hydroxysteroid dehydrogenase isozymes by growth hormone and insulin-like growth factor: in vivo and in vitro studies.  J Clin Endocrinol Metab. 1999;  84 4172-4177
• 18 Sun K, Yang K, Challis JR. Regulation of 11beta-hydroxysteroid dehydrogenase type 2 by progesterone, estrogen, and the cyclic adenosine 5′-monophosphate pathway in cultured human placental and chorionic trophoblasts.  Biol Reprod. 1998;  58 1379-1384
• 19 Sumitomo M, Milowsky M, Shen R, Navarro D, Dai J, Asano T, Hayakawa M, Nanus DM. Neutral endopeptidase inhibits neuropeptide-mediated transactivation of the insulin-like growth factor receptor-Akt cell survival pathway.  Cancer Res. 2001;  61 3294-3298
• 20 Nath N, Lakshmi V, Rosenthal JC. Presence of 11 beta-hydroxysteroid dehydrogenase enzyme in the human prostate tumor cell line LNCaP.  Prostate. 1993;  23 225-233
• 21 Zhu J, Gong JY, Goodman OB, Cartegni L, Nanus DM, Shen R. Bombesin attenuates pre-mRNA splicing of glucocorticoid receptor by regulating the expression of serine-arginine protein p30c (SRp30c) in prostate cancer cells.  BBA-Mol, Cell Res. 2007;  1773 1087-1094
• 22 Abrahamsson PA. Neuroendocrine differentiation in prostatic carcinoma.  Prostate. 1999;  39 135-148
• 23 Sumitomo M, Shen R, Goldberg JS, Dai J, Navarro D, Nanus DM. Neutral endopeptidase promotes phorbol ester-induced apoptosis in prostate cancer cells by inhibiting neuropeptide-induced protein kinase δ degradation.  Cancer Res. 2000;  60 6590-6596
• 24 Zheng R, Iwase A, Shen R, Goodman OB, Sugimoto N, Takuwa Y, Lerner DJ, Nanus DM. Neuropeptide stimulated cell migration in prostate cancer cells is mediated by RhoA kinase signaling and inhibited by neutral endopeptidase.  Oncogene. 2006;  25 5942-5952
• 25 Dai J, Shen R, Nanus DM. Synergistic activation of androgen recep-tor by bombesin and low-dose androgen.  Clin Cancer Res. 2002;  8 2399-2405
• 26 Paulsen SK, Pedersen SB, Jørgensen JO, Fisker S, Christiansen JS, Flyvbjerg A, Richelsen B. Growth Hormone (GH) substitution in GH-deficient patients inhibits 11ß-hydroxysteroid dehydrogenase type 1 messenger ribonucleic acid expression in adipose tissue.  J Clin Endocrinol Metab. 2006;  91 1093-1098
• 27 Tomlinson JW, Walker EA, Bujalska IJ, Draper N, Lavery GG, Cooper MS, Hewison M, Stewart PM. 11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response.  Endocrine Rev. 2004;  25 831-866
• 28 Levine L, Lucci  3rd  JA, Pazdrak B, Cheng JZ, Guo YS, Townsend Jr CM, Hellmich MR. Bombesin stimulates nuclear factor kappa B activation and expression of proangiogenic factors in prostate cancer cells.  Cancer Res. 2003;  63 3495-3502
• 29 Inoue K, Slaton JW, Eve BY, Kim SJ, Perrotte P, Balbay MD, Yano S, Bar-Eli M, Radinsky R, Pettaway CA, Dinney CPN. Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer.  Clin Cancer Res. 2000;  6 2104-2109
• 30 Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target.  Nature. 2005;  438 967-974
• 31 Hauk PJ, Hamid QA, Chrousos GP, Leung DY. Induction of corticosteroid insensitivity in human PBMCs by microbial superantigens.  J Allergy Clin Immunol. 2005;  105 782-787
• 32 Herr I, Gassler N, Friess H, Buchler MW. Regulation of differential pro- and anti-apoptotic signaling by glucocorticoids.  Apoptosis. 2007;  12 271-291
• 33 Flaig TW, Bargawi A, Miller G, Kane M, Zeng C, Crawford ED, Glodé LM. A phase II trial of dexamethasone, vitamin D, and carboplatin in patients with hormone-refractory prostate cancer.  Cancer. 2006;  107 266-274

Correspondence